Cancer Institute A national cancer institute
designated cancer center

Heather Wakelee

Publication Details

  • A phase I pharmacokinetic study of bexarotene with vinorelbine and cisplatin in patients with advanced non-small-cell lung cancer (NSCLC).

    Wakelee HA, Middleton G, Dunlop D, Ramlau R, Leighl N, Hao D, Lopez-Anaya A, Zatloukal P, Jacobs CD. Cancer Chemother Pharmacol. 2012; 69 (3): 815-24

    This is a phase I study of the retinoid X receptor agonist bexarotene (Targretin(®)) in combination with the chemotherapeutic drugs cisplatin and vinorelbine and lipid-lowering therapy. This study looked for pharmacokinetic (PK) interactions between the agents in parallel with a phase III study of the combination.

    PubMedID: 22057854

Stanford Medicine Resources:

Footer Links: